IFRX Rasio cepet InflaRx NV

InflaRx N.V. (IFRX) develops unique monoclonal antibodies to suppress inflammation in critical pathologies, leveraging a robust R&D division. Serving as the primary valuation tool, this price chart highlights the issuer's stability dependence on existing reserves prior to the certification of new drugs, with the current ratio standing at 8.52. The scaling of bioproduct output is facilitated through effective partnerships with external contract manufacturing organizations.

The quick ratio measures a company's ability to instantaneously settle short-term liabilities using only cash and accounts receivable, excluding slow-moving inventories. By analyzing the state of quick liquidity, an investor assesses the financial resilience of InflaRx N.V. (IFRX) against cash flow gaps, which is critical for ensuring the expansion of the anti-C5a platform and scaling drug supplies to the hospital sector.